Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B: The Subgroup (N=33) With No Neutralizing Anti-AAV Antibodies (NAb-Negative):
- 100% expressed endogenous FIX at therapeutic levels (mean 39.0 IU/dL)
- 100% remained prophylaxis-free over 4 years—zero returned to prophylaxis
- Exogenous FIX consumption decreased by 99%
- 85% reduction in bleeds (all, spontaneous, joint)
- Safety: Treatment-related AEs only first 3 months; transient ALT elevations 18%, all manageable
This enables direct comparison to other haemophilia B gene therapies where only NAb-negative patients were enrolled.
HOPE-B’s Inclusive Design
HOPE-B is the first—and currently only—haemophilia B gene therapy trial to include patients with pre-existing AAV neutralizing antibodies for treatment with etranacogene dezaparvovec.
Very recently, the NEJM paper presented 5-year data of the full cohort (NAb-negative and NAb-positive; N=54).
Congratulations to Priyanka Raheja and co-authors!”
Read the full article here.
Article: Etranacogene dezaparvovec in participants with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)
Authors: Priyanka Raheja, Niamh O’Connell, Peter Verhamme, Peter Kampmann, Richard S. Lemons, Fei Wang, Sean Gill, Paul E. Monahan, Sandra Le Quellec, Frank W. G. Leebeek
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026